InMed receives NASDAQ delisting notice

InMed Pharmaceuticals ( NASDAQ: INM ) has timely requested a hearing before the Nasdaq Listing Qualifications Panel to appeal the determination by Nasdaq, and present its plan to regain and sustain compliance. Nasdaq has notified the company via electronic mail that the Hearing has been scheduled for October 31, 2024. Source: Press Release More on InMed Pharmaceuticals Financial information for InMed Pharmaceuticals.